Disclosed are compositions and methods for their use for reducing tumor necrosis factor alpha (TNF-.alpha.) and/or vascular endothelial growth factor (VEGF) production in skin cells by topically applying to skin in need thereof, a composition comprising an effective amount of Opuntia ficus-indica tuna, Opuntia ficus-indica nopales, or both, or extracts thereof, to reduce TNF-.alpha. or VEGF production in skin cells.

Mary Kay Inc.

Topical cosmetic compositions

The present invention relates to a pharmaceutical composition comprising a compound of formula (1), (2) or (3) as defined in the specification for the prevention or treatment of diseases associated with oxidative stress, mitochondria dysfunction, hypoxic injury, necrosis and/or ischemic reperfusion injury, and a cosmetic composition comprising an indole compound having an antioxidant effect.

LG CHEM, LTD.

Pharmaceutical composition comprising indole compound

The present invention relates to novel peptides derived from an EDAR (EDAR receptor) ligand which belongs to TNF (tumor necrosis factor)-.alpha. family and to uses of the same. The present peptides of EDA3 derived from EDA and EDphD1 derived from EDAR ligand possess identical or similar activities to naturally occurring EDA and have much higher stability and skin penetration potency than naturally occurring EDA. Therefore, the composition containing the present peptide not only shows excellent effects on improvement in hair loss and promotion of hair growth, but also has superior efficacies on treatment of an EDA signal transduction pathway-related disorder. In addition, the outstanding activity and stability of the present peptide described above may be greatly advantageous in application to pharmaceutical compositions, quasi-drugs and cosmetics.

cosmetic/necrosis

Topical cosmetic compositions

Pharmaceutical composition comprising indole compound

EDAR ligand derived peptides and use thereof

Den mest komplette databasen med medisinske urter støttet av vitenskap